Future strategies targeting these Npas4-regulated pathways could be a novel approach to develop therapeutic treatments for hypofrontality and anhedonia-related symptoms in patients struggling with depression, bipolar disorder, and other stress-related neuropsychiatric disorders. This evidence concerns the gene NPAS4 and depressive symptom measurement.